Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma

Summary

This study is designed to test the the protective capacity of Goserelin compared with oral contraceptive

Timeline

Start

2004-01

Primary completion

2009-09

Completion

2009-09

Outcome

Missed primary endpoint

paper No protection of the ovarian reserve with hormonal co-treatment during BEACOPPesc. PMID 20305034 ↗

paper For the entire study cohort, the respective ovarian follicle preservation rate was 0% (95% confidence interval 0% to 12%). PMID 20305034 ↗

Publications

• Results Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Pluetschow A, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010 Oct;21(10):2052-2060. doi: 10.1093/annonc/mdq066. Epub 2010 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Goserelin	Other / unclassified	—	—

Indications